Avenciguat (BI 685509)

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyHypertension, PortalLiver DiseasesScleroderma, Systemic

Phase 1

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

TerminatedNCT06272058

Boehringer IngelheimHealthy, Liver Diseases

Start: 2024-05-03End: 2024-07-02Updated: 2025-07-17

Phase 2

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

TerminatedNCT05161481

Boehringer IngelheimHypertension, Portal

Start: 2022-04-27End: 2024-06-12Updated: 2025-09-03

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

CompletedNCT05559580

Boehringer IngelheimScleroderma, Systemic

Start: 2022-12-13End: 2026-01-30Updated: 2026-03-17

Related Papers

Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis.

2025-08-012 citations

A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study

Journal of Scleroderma and Related Disorders2024-11-073 citations

Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials

Naunyn-Schmiedeberg s Archives of Pharmacology2024-05-245 citations

Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study

Hepatology Communications2023-10-279 citations

The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

Trials2023-04-2410 citations